Thera-SAbDab

SPARTALIZUMAB

>   Structural Summary
TherapeuticSpartalizumab
TargetPDCD1
Heavy ChainEVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedAsan Medical Center, Dana-Farber Cancer Institute, Novartis, Novartis Oncology, Palobiofarma, Seoul National University Hospital
Conditions Approvedna
Conditions ActiveMalignant melanoma, Breast cancer, Colorectal cancer, Diffuse large B cell lymphoma, Gastric cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Solid tumours, Acute myeloid leukaemia, Cancer, Liver cancer, Lymphoma, Multiple myeloma, Myelodysplastic syndromes, Ovarian cancer, Pancreatic cancer, Renal cancer
Conditions DiscontinuedNeuroendocrine tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]